Counsel to LAVA Therapeutics in Multimillion-Dollar Global License Agreement
Served as IP counsel to client LAVA Therapeutics, a clinical-stage immuno-oncology company, in a multimillion-dollar global license agreement with Seagen, Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies. The exclusive license agreement will enable Seagen to develop, manufacture and commercialize LAVA-1223, an advanced preclinical asset that utilizes LAVA’s proprietary Gammabody™ technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors, most commonly associated with colorectal, lung, head and neck cancer.